Register for our free email digests:
Pennington Biomedical Research Center
Latest From Abbott Vascular
The US Market for interventional cardiology products, which includes diagnostic and therapeutic products, is anticipated to expand from an estimated $3.3 billion in 2015 to roughly $3.6 billion in total product sales by the year 2020. One bright spot in this otherwise lackluster market is the interventional diagnostic products segment, which is projected to grow at CAGR of 4.7% and reach almost $1 billion by 2020, according to a report by Medtech Insight.
Drug-coated balloon (DCBs) catheters have become the latest weapon in the fight against peripheral artery disease in the US, although they have been in use in Europe for some time. While the number of procedures employing DCBs is still dwarfed by conventional angioplasty procedures, they are expected to grow at a much faster rate, fueling a market projected to reach $1 billion by 2020; meanwhile other procedures such as mechanical atherectomy are also expected to show significant growth.
The agency's alert, which is not tied to any specific manufacturer or product, states that peeling coatings have led to 11 recalls since 2010 and 500 adverse event reports since 2014.
INTERVIEW: Bioabsorbable Stents? No, Drug-Filled Stents Is Way Forward, Says Medtronic Cardiac Intervention CMO
The world’s largest medtech pureplay, Medtronic, believes drug-filled stents (DFSs) will be a major advance in coronary stent technology, which is why it is bypassing bioabsorable technologies like Abbott’s Absorb BVS stent and planning its next steps toward bringing DFSs to market.
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.